LGND insider transactions
Ligand Pharmaceuticals Incorporated (LGND) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for LGND
- CLO & Secretary Reardon Andrew sold $1,135,316 worth of shares (5,000 units at $227.06) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio exercised 1,736 shares at a strike of $57.58, increasing direct ownership by 7% to 27,679 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $563,080 worth of shares (2,501 units at $225.14) as part of a pre-agreed trading plan and exercised 2,034 shares at a strike of $69.51, decreasing direct ownership by 1% to 41,786 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew exercised 5,000 shares at a strike of $52.27 and sold $1,156,556 worth of shares (5,000 units at $231.31) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Kozarich John W4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Reardon Andrew4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Lamattina John L4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Espinoza Octavio4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Davis Todd C4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Reardon Andrew4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Sabba Stephen L4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio exercised 2,405 shares at a strike of $92.65 and sold $687,825 worth of shares (3,057 units at $225.00), decreasing direct ownership by 3% to 21,010 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew exercised 5,000 shares at a strike of $52.27 and sold $1,031,770 worth of shares (5,000 units at $206.35) (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio exercised 2,073 shares at a strike of $63.49 and sold $2,762,822 worth of shares (13,423 units at $205.83), decreasing direct ownership by 34% to 21,662 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Sabba Stephen L exercised 2,034 shares at a strike of $69.51 and sold $409,851 worth of shares (2,034 units at $201.50) (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $93,632 worth of shares (467 units at $200.50), decreasing direct ownership by 1% to 42,720 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew was granted 15,738 shares and covered exercise/tax liability with 9,680 shares, increasing direct ownership by 20% to 36,869 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio was granted 16,200 shares and covered exercise/tax liability with 11,763 shares, increasing direct ownership by 16% to 33,012 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Executive Officer Davis Todd C was granted 60,426 shares and covered exercise/tax liability with 32,877 shares, increasing direct ownership by 17% to 188,886 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $91,490 worth of shares (467 units at $195.91), decreasing direct ownership by 1% to 43,187 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $88,532 worth of shares (467 units at $189.58), decreasing direct ownership by 1% to 43,654 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio acquired $765 worth of shares (8 units at $95.68), increasing direct ownership by 0.03% to 28,575 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SEC Form 4 filed by Director Ligand Pharmaceuticals Inc4 - LIGAND PHARMACEUTICALS INC (0000886163) (Reporting)
- Chief Financial Officer Espinoza Octavio exercised 2,381 shares at a strike of $69.00, increasing direct ownership by 9% to 28,567 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio sold $339,711 worth of shares (1,804 units at $188.31), decreasing direct ownership by 6% to 26,186 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio covered exercise/tax liability with 1,862 shares, decreasing direct ownership by 6% to 27,990 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Aryeh Jason exercised 2,034 shares at a strike of $69.51, increasing direct ownership by 3% to 71,323 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Executive Officer Davis Todd C gifted 130 shares, decreasing direct ownership by 0.08% to 161,337 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $91,457 worth of shares (467 units at $195.84), decreasing direct ownership by 1% to 44,121 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Gray Nancy Ryan exercised 6,571 shares at a strike of $69.58 and sold $1,350,012 worth of shares (6,571 units at $205.45) (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Lamattina John L exercised 4,179 shares at a strike of $67.78 and sold $858,576 worth of shares (4,179 units at $205.45) (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $89,219 worth of shares (467 units at $191.05), decreasing direct ownership by 1% to 44,588 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $83,800 worth of shares (467 units at $179.44), decreasing direct ownership by 1% to 45,055 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Aryeh Jason sold $1,708,088 worth of shares (10,000 units at $170.81), decreasing direct ownership by 13% to 69,289 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Zimmermann Martine covered exercise/tax liability with 115 shares, decreasing direct ownership by 3% to 4,443 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $75,775 worth of shares (467 units at $162.26), decreasing direct ownership by 1% to 45,522 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew covered exercise/tax liability with 1,325 shares, decreasing direct ownership by 4% to 30,811 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $61,586 worth of shares (467 units at $131.88), decreasing direct ownership by 1% to 45,989 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W sold $116,750 worth of shares (934 units at $125.00), decreasing direct ownership by 2% to 46,456 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew acquired $21,221 worth of shares (233 units at $91.08), increasing direct ownership by 0.73% to 32,136 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio acquired $20,401 worth of shares (224 units at $91.08), increasing direct ownership by 0.76% to 29,852 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Executive Officer Davis Todd C acquired $21,221 worth of shares (233 units at $91.08), increasing direct ownership by 0.14% to 161,467 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Amendment: New insider Espinoza Octavio claimed ownership of 1,696 shares (SEC Form 3)3/A - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew sold $57,042 worth of shares (500 units at $114.08), decreasing direct ownership by 2% to 31,903 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew sold $57,271 worth of shares (500 units at $114.54), decreasing direct ownership by 2% to 32,403 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Gray Nancy Ryan was granted 1,209 shares, increasing direct ownership by 18% to 8,094 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Aryeh Jason was granted 1,209 shares, increasing direct ownership by 2% to 79,289 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Lamattina John L was granted 1,209 shares, increasing direct ownership by 4% to 30,724 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Zimmermann Martine was granted 1,209 shares and covered exercise/tax liability with 188 shares, increasing direct ownership by 29% to 4,558 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Sabba Stephen L was granted 1,209 shares, increasing direct ownership by 4% to 33,793 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W was granted 1,209 shares, increasing direct ownership by 3% to 47,390 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Haas Jason was granted 1,209 shares, increasing direct ownership by 22% to 6,606 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew covered exercise/tax liability with 897 shares and sold $104,000 worth of shares (1,000 units at $104.00), increasing direct ownership by 46% to 32,903 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Kozarich John W exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 5% to 46,181 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Director Sabba Stephen L exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 8% to 32,584 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- CLO & Secretary Reardon Andrew was granted 6,415 shares, increasing direct ownership by 23% to 34,783 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Financial Officer Espinoza Octavio sold $575,148 worth of shares (5,000 units at $115.03) and was granted 7,484 shares, increasing direct ownership by 10% to 26,363 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- Chief Executive Officer Davis Todd C was granted 21,382 shares, increasing direct ownership by 16% to 151,724 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)